Transforming mental health services
Paul Midgley, of Wilmington Healthcare, explores the NHS Long Term Plan’s strategy for tackling mental health conditions
PharmaTimes Magazine Archive
Magazine highlights
View more from the latest edition
It’s a small world
To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation
The liberation of patient data
Aiden Flynn explores how the collection and analysis of real-world patient data can be an invaluable asset in clinical development
Technology in focus: the Liqui-Pellet
University of Sussex researcher Matthew Lam talks to PharmaTimes about a new oral dosage technology developed to help tackle bioavailability challenges
Changing tack
Think the old product launch playbook is still relevant? Think again.
Making sense of it
As life sciences companies’ international ambitions grow, and global regulatory scrutiny in parallel, managing translated content is becoming ever more complex. So the promise of neural machine learning as a potential solution is appealing. But just how far can the technology go in reducing workloads and improving accuracy and turnaround times?
The promise of gene editing
Christopher Vakulskas says the rapid progress seen in gene editing is exciting, but there are still challenges in the field to overcome if its full potential is to be reached
The strongest link?
Jennifer Bradford and Matthew Metherell consider the success and potential of artificial intelligence in clinical research and the impact of machine learning on clinical trials
